Awards need to also recognize researchers whose work has an impact on policy and can be translated for policy makers and even the broader public to understand, said Dana Goldman, PhD, the Leonard D. Schaeffer Chair and director of the USC Leonard D. Schaeffer Center for Health Policy and Economics and Professor of Public Policy, Pharmacy, and Economics at the USC Sol Price School of Public Policy and USC School of Pharmacy.
Awards need to also recognize researchers whose work has an impact on policy and can be translated for policy makers and even the broader public to understand, said Dana Goldman, PhD, the Leonard D. Schaeffer Chair and director of the USC Leonard D. Schaeffer Center for Health Policy and Economics and Professor of Public Policy, Pharmacy, and Economics at the USC Sol Price School of Public Policy and USC School of Pharmacy.
Transcript
Why should academic institutions nominate exemplary candidates for awards such as the Seema S. Sonnad Emerging Leader in Managed Care Research Award?
Academic institutions have a problem that they tend to reward scientific publications and our ability to communicate to scientific audiences. But it’s increasingly important in today’s world that we come out of the ivory tower and we have an impact in policy circles and with the broader public, and that includes the media, as well. And Dr. Trish’s work has shown that she can have an impact on all those arenas.
So, I think it’s very important that academic institutions reward people who can translate evidence into policy. One of the things we’ve tried to do at the Schaeffer Center is to make sure that that activity is supported, that is translating evidence into policy. And Erin Trish exemplifies that, perfectly.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More